OncoVAX--Offered by Vaccinogen, OncoVAX is an active-specific immunotherapeutic for the post-surgical treatment of patients diagnosed with Stage II colon cancer.
Vaccinogen, which acquired OncoVAX from Intracel in 2007, has provided this vaccine to patients with colon cancer in Switzerland in conjunction with surgery.
The Bandung-based company was set up in August 1890 then named Parc Vaccinogen
or Land Koepok Inrichting, later famous as Pasteur Institute.
The key future market players covered are Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Debiopharm Group, Merck KGaA, Regeneron, Vaccinogen
Clinipace Worldwide, a global full-service clinical research organization (CRO), announced today that Vaccinogen, a biotechnology company with more than three decades experience researching how to combat cancer using the body's own immune system, has selected the company to manage a pivotal phase 3b confirmatory trial for OncoVAX[R] in the treatment of Stage II Colon Cancer.
Vaccinogen is the producer of OncoVAX[R], an autologous immunotherapy vaccine [EMA classified Advanced Therapeutic Medicinal Product (ATMP)] for the adjuvant treatment of Stage II colon cancer.
Vaccinogen begins its study with Clinipace on the heels of recent news announcing the first autologous immunotherapy approved by the FDA to treat cancer - Dendreon's Provenge, a breakthrough cancer vaccine that promises to extend the lives of men with advanced prostate cancer.
Additionally, it is in large, complex trials like this one that our technology platform, and the visibility and control it will provide Vaccinogen, becomes essential.
Other companies presenting as part of the Cancer Immunotherapies track include Dendreon, BioVex, GlaxoSmithKline and Vaccinogen
In addition to BioSante, the other companies on the panel will be Dendreon, GlaxoSmithKline Biologicals, BioVex, Biovest, Vaccinogen